Since December, when cases of a then-unknown respiratory disease were first reported in Wuhan, China, APHA has working to share information and ensure that public health has the resources it needs to address COVID-19.

Forty miles from the state capital, Jackson County, West Virginia, is home to about 29,000 people and 25 hospital beds. Like much of the state, the rural county is reeling from the opioid epidemic.

The current coronavirus 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) infection, raises important questions as to whether pre-morbid use or continued administration of inhaled corticosteroids (ICS) affects the outcomes of acute respiratory infections due to coronavirus. Many physicians are concerned about whether individuals positive for SARS-CoV-2 and taking ICS should continue them or stop them, given that ICS are often regarded as immunosuppressive. A number of key questions arise. Are people with asthma or COPD at increased risk of developing COVID-19? Do ICS modify this risk, either increasing or decreasing it? Do ICS influence the clinical course of COVID-19? (figure 1). Whether ICS modify the risk of developing COVID-19 or the clinical course of COVID-19 in people who do not have lung disease should also be considered (figure 1).

The aim of this study was to identify factors associated with the death of patients with COVID-19 pneumonia caused by the novel coronavirus SARS-CoV-2.

All clinical and laboratory parameters were collected prospectively from a cohort of patients with COVID-19 pneumonia who were hospitalised to Wuhan Pulmonary Hospital (Wuhan City, Hubei Province, China) between 25 December 2019 and 7 February 2020. Univariate and multivariate logistic regression was performed to investigate the relationship between each variable and the risk of death of COVID-19 pneumonia patients.

In total, 179 patients with COVID-19 pneumonia (97 male and 82 female) were included in the present prospective study, of whom 21 died. Univariate and multivariate logistic regression analysis revealed that age ≥65 years (OR 3.765, 95% CI 1.146-17.394; p=0.023), pre-existing concurrent cardiovascular or cerebrovascular diseases (OR 2.464, 95% CI 0.755-8.044; p=0.007), CD3⁺CD8⁺ T-cells ≤75 cells·μL^–1 (OR 3.982, 95% CI 1.132-14.006; p<0.001) and cardiac troponin I ≥0.05 ng·mL^–1 (OR 4.077, 95% CI 1.166-14.253; p<0.001) were associated with an increase in risk of mortality from COVID-19 pneumonia. In a sex-, age- and comorbid illness-matched case–control study, CD3⁺CD8⁺ T-cells ≤75 cells·μL^–1 and cardiac troponin I ≥0.05 ng·mL^–1 remained as predictors for high mortality from COVID-19 pneumonia.

We identified four risk factors: age ≥65 years, pre-existing concurrent cardiovascular or cerebrovascular diseases, CD3⁺CD8⁺ T-cells ≤75 cells·μL^–1 and cardiac troponin I ≥0.05 ng·mL^–1. The latter two factors, especially, were predictors for mortality of COVID-19 pneumonia patients.

The coronavirus disease 2019 (COVID-19) epidemic, which was first reported in December 2019 in Wuhan, China, has caused 80 904 confirmed cases as of 9 March 2020, with 28 673 cases being reported outside of China. It has been declared a pandemic by the World Health Organization (WHO), has exhibited human-to-human transmissibility and has spread rapidly across countries [1]. Although the Chinese government has taken various measures to control city-to-city transmission (e.g. shutting down cities, extending holidays) and many other countries have implemented measures (such as airport screening and testing patients who have reported symptoms), the number of cases is still increasing quickly throughout the world.

Governments around the world must rapidly mobilize and make difficult policy decisions to mitigate the coronavirus disease 2019 (COVID-19) pandemic. Because deaths have been concentrated at older ages, we highlight the important role of demography, particularly, how the age structure of a population may help explain differences in fatality rates...

As the novel coronavirus spreads, communities across the United States are struggling to offer public testing. The need is urgent. Testing got off to a delayed start in the United States as a result of technical missteps and a slow response from government officials. Now cities across the country are...

In December 2019, a novel coronavirus causing an infectious respiratory disease (COVID-19) was identified, which since then has developed into a pandemic with higher rates of mortality in older individuals and those with underlying medical conditions.¹ Multiple sclerosis (MS) is an immune-mediated neurologic disease which requires long-term treatment with immunotherapies that have been shown to increase the risk of infections.² As a result, there is significant anxiety among patients and neurologists during the pandemic regarding the infection outcome in this patient population. We present a patient with MS treated with fingolimod who was diagnosed with COVID-19 and had a favorable outcome.

At the time of this writing, healthcare systems are facing worldwide the pandemic of the coronavirus severe acute respiratory coronavirus 2 (SARS-COV-2) and its associated disease, named cronavirus disease 19 (COVID-19). This virus is a new human pathogen, and currently, there are no specific treatment options.¹ COVID-19 mostly affects the respiratory system, ranging from mild flu-like symptoms to severe pneumonia, but extrarespiratory multisystemic involvement has also been reported.² Li et al.³ recently described the neuroinvasive potential of COVID-19, but, to our knowledge, no case of acute dysimmune neuropathy has been described so far. Here, the authors report the case of an acute and severe peripheral nervous system disorder possibly related to COVID-19 infection.

On 31 December 2019, the World Health Organization was informed of a cluster of cases of pneumonia of unknown etiology in Wuhan, China. Subsequent investigations identified a novel coronavirus, now named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), from the affected patients. Highly sensitive and specific laboratory diagnostics are important for controlling the rapidly evolving SARS-CoV-2-associated coronavirus disease 2019 (COVID-19) epidemic. In this study, we developed and compared the performance of three novel real-time reverse transcription-PCR (RT-PCR) assays targeting the RNA-dependent RNA polymerase (RdRp)/helicase (Hel), spike (S), and nucleocapsid (N) genes of SARS-CoV-2 with that of the reported RdRp-P2 assay, which is used in >30 European laboratories. Among the three novel assays, the COVID-19-RdRp/Hel assay had the lowest limit of detection in vitro (1.8 50% tissue culture infective doses [TCID₅₀]/ml with genomic RNA and 11.2 RNA copies/reaction with in vitro RNA transcripts). Among 273 specimens from 15 patients with laboratory-confirmed COVID-19 in Hong Kong, 77 (28.2%) were positive by both the COVID-19-RdRp/Hel and RdRp-P2 assays. The COVID-19-RdRp/Hel assay was positive for an additional 42 RdRp-P2-negative specimens (119/273 [43.6%] versus 77/273 [28.2%]; P < 0.001), including 29/120 (24.2%) respiratory tract specimens and 13/153 (8.5%) non-respiratory tract specimens. The mean viral load of these specimens was 3.21 x 10⁴ RNA copies/ml (range, 2.21 x 10² to 4.71 x 10⁵ RNA copies/ml). The COVID-19-RdRp/Hel assay did not cross-react with other human-pathogenic coronaviruses and respiratory pathogens in cell culture and clinical specimens, whereas the RdRp-P2 assay cross-reacted with SARS-CoV in cell culture. The highly sensitive and specific COVID-19-RdRp/Hel assay may help to improve the laboratory diagnosis of COVID-19.

Infection with the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may remain asymptomatic, leading to under-recognition of the related disease, coronavirus disease, 2019 (COVID-19), and to incidental findings in nuclear imaging procedures performed for standard clinical indications. Here, we report about our local experience in a region with high COVID-19 prevalence and dynamically increasing infection rates. Methods: Within the 8-d period of March 16–24, 2020, hybrid imaging studies of asymptomatic patients who underwent ¹⁸F-FDG PET/CT or ¹³¹I SPECT/CT for standard oncologic indications at our institution in Brescia, Italy, were analyzed for findings suggestive of COVID-19. The presence, radiologic features, and metabolic activity of interstitial pneumonia were identified, correlated with the subsequent short-term clinical course, and described in a case series. Results: Six of 65 patients (9%) who underwent PET/CT for various malignancies showed unexpected signs of interstitial pneumonia on CT and elevated regional ¹⁸F-FDG avidity. Additionally, 1 of 12 patients who received radioiodine for differentiated thyroid carcinoma also showed interstitial pneumonia on SPECT/CT. Five of 7 patients had subsequent proof of COVID-19 by reverse-transcriptase polymerase chain reaction. The remaining 2 patients were not tested immediately but underwent quarantine and careful monitoring. Conclusion: Incidental findings suggestive of COVID-19 may not be infrequent in hybrid imaging of asymptomatic patients in regions with an expansive spread of SARS-CoV-2. Nuclear medicine services should prepare accordingly.

Background

We aimed to investigate the epidemiological and clinical features, and medical care-seeking process of patients with the 2019 coronavirus disease (COVID-19) in Wuhan, China, to provide useful information to contain COVID-19 in other places with similar outbreaks of the virus.

Methods

We collected epidemiological and clinical information of patients with COVID-19 admitted to a makeshift Fangcang hospital between 7 and 26 February, 2020. The waiting time of each step during the medical care-seeking process was also analysed.

Results

Of the 205 patients with COVID-19 infection, 31% had presumed transmission from a family member. 10% of patients had hospital-related transmission. It took as long as a median of 6 days from the first medical visit to receive the COVID-19 nucleic acid test and 10 days from the first medical visit to hospital admission, indicating early recognition of COVID-19 was not achieved at the early stage of the outbreak, although these delays were shortened later. After clinical recovery from COVID-19, which took a mean of 21 days from illness onset, there was still a substantial proportion of patients who had persistent SARS-CoV-2 infection.

Conclusions

The diagnostic evaluation process of suspected patients needs to be accelerated at the epicentre of the outbreak and early isolation of infected patients in a healthcare setting rather than at home is urgently required to stop the spread of the virus. Clinical recovery is not an appropriate criterion to release isolated patients and as long as 4 weeks' isolation for patients with COVID-19 is not enough to prevent the spread of the virus.

As cancer researchers shutter their labs to comply with COVID-19–related work restrictions, some are turning their attention, resources, and technical know-how to the challenge of tackling the deadly coronavirus.

As the COVID-19 pandemic worsens, the clinical cancer community is grappling with how to continue providing access to experimental but potentially lifesaving therapies while keeping immunocompromised patients safe. To that end, cancer centers are making changes to their clinical trial programs, while pharmaceutical companies are deciding how—or whether—trials should continue.

As COVID-19 continues to surge, cancer scientists engaged in basic research face unique challenges. At centers throughout the United States, investigators are confronting difficult decisions about which experiments to continue, while securing supplies and creating contingency plans for a complete shutdown.

Bán shophouse mặt tiền quận 8 thanh toán 3,4 tỷ. Còn lại trả góp. - Hình thức: 1 trệt 1 lầu (được xây thêm 1 lửng). - Sổ hồng vĩnh viễn.Diện tích 151m2 đối diện công viên, gần trường học và dân cư và lưu lượng khách vài ngàn người mỗi ngày.Liên hệ: Mỹ Linh: Trưởng phòng kinh doan...

Tập đoàn Hưng Thịnh áp dụng chính sách chiết khấu cực khủng lên đến 40% tổng giá trị cho khách hàng mua Đất nền biệt thự vườn Sài Gòn Garden Riverside Village tại Khu Đảo Ngọc Long Phước Q9. Tên dự án: Biệt Thự Vườn Saigon Garden Riverside Village. * Quy mô: 168 căn biệt thự vườn...

“Mùa Covid-19”, các nhà đầu tư bất động sản muốn “sống khỏe” cần lưu ý những gì? Liệu có còn cơ hội đầu tư ngắn hạn hoặc lướt sóng trong 6-12 tháng tới?

[CÓ HẸN VỚI CHUYÊN GIA BẤT ĐỘNG SẢN #23] Lựa chọn mua nhà vào thời điểm dịch Covid-19 có phải là sáng suốt? Những nhà đầu tư vốn mỏng muốn tham gia thị trường lúc này cần lưu ý những gì?

Đồng hành cùng độc giả và khách hàng vượt qua đại dịch Covid-19, Batdongsan.com.vn lập chủ đề nóng "BĐS & Covid-19" để cập nhật nhanh và toàn diện nhất mọi chuyển động của thị trường bất động sản Việt Nam trong thời kỳ dịch bệnh. Loại hình bất động sản nào bị ảnh hưởng mạnh nhất (chung cư, biệt thự, đất nền, nhà riêng, nhà mặt phố...)? Giá nhà đất biến động ra sao? Nhà đầu tư có lựa chọn như thế nào để bảo toàn dòng tiền? Có nên mua nhà vào thời điểm này? Những lưu ý cho người mua, bán, đầu tư nhà đất từ góc nhìn chuyên gia... Tất cả các nội dung sẽ được cập nhật đầy đủ trong chủ đề "BĐS & Covid-19".

Nhà mặt phố tại ĐC: 36 Chu Huy Mân, Phúc Đồng, long Biên, Hà Nội được xây dựng theo phong cách hiện đại kết hợp với tân cổ điển như KS 5* cao cấp mà giá lại vô cùng “hạt rẻ”. Link Video từ nền móng đến hoàn thiện công trình: https://www.youtube.com/watch?v=Vbd0S8Z32fE Khu vực Lon...

- Thiết kế thông sàn, phù hợp cho ngân hàng, siêu thị, showroom, salon, spa, phòng khám, mầm non, chuyển phát, game.. V. V. V.- Diện tích: 100m2 x 2 tầng.- Mặt tiền: 6.8m.- Tòa nhà mới đã trang bị đủ thiết bị điện nước, điều hòa tổng, vách kính, thang máy, có hầm để xe ôto xe máy...

Trước tình trạng dịch Covid-19 đang diễn biến phức tạp, nhiều công ty đã tạo điều kiện cho nhân viên làm việc tại nhà, hủy bỏ các cuộc họp không cần thiết nhằm hạn chế sự lây lan của dịch bệnh. Để đảm bảo hiệu suất công việc khi làm tại nhà, việc bài trí góc làm việc khoa học, ngăn nắp và tràn đầy cảm hứng rất cần được chú trọng.

As they implement stricter measures and distribute millions worth of donations to communities in need.

Mới đây, Hiệp hội Bất động sản Việt Nam (VNREA) đã có công văn gửi Chủ tịch Quốc hội nhằm kiến nghị hoàn thiện chính sách pháp luật và tháo gỡ khó khăn cho doanh nghiệp bất động sản.

Theo Nghị định vừa được Thủ tướng Nguyễn Xuân Phúc ban hành, các doanh nghiệp bất động sản đã lọt danh sách được “giải cứu” do ảnh hưởng bởi dịch Covid-19.

Chính phủ vừa ban hành Nghị định 41/2020/NĐ-CP về gia hạn thời gian nộp thuế và tiền thuê đất, tuy nhiên nhiều doanh nghiệp bất động sản bày tỏ mong muốn kéo dài thời gian gia hạn lên 1 năm.

Giai đoạn khó khăn của nền kinh tế Việt Nam vừa trôi qua khi dịch Covid-19 đã được kiểm soát hoàn toàn. Thị trường trong nước nhanh chóng phục hồi với sự tăng tốc của các kênh đầu tư tài chính chứng khoán và bất động sản. Dù vậy, bất động sản vẫn được đánh giá là kênh đầu tư có triển vọng sinh lời và ít tiềm ẩn rủi ro hơn cả.

[CÓ HẸN VỚI CHUYÊN GIA BẤT ĐỘNG SẢN #24] Cuộc khủng hoảng của thị trường bất động sản do Covid-19 có nghiêm trọng hơn so với giai đoạn khủng hoảng tài chính 2008-2013? “Trong nguy có cơ”, vậy dịch bệnh đã cho thấy những cơ hội gì trên thị trường?

Đến thời điểm này, Việt Nam đã có thể tự hào với thế giới khi là 1 trong những nước đầu tiên khống chế thành công dịch Covid-19. Giãn cách xã hội từng bước được nới lỏng, kinh tế xã hội dần trở lại nhịp sống bình thường. Việt Nam đang tiến gần tới “chiến thắng kép” như Thủ tướng Chính phủ đã chỉ đạo.